ESMO 2023 Insights: "Alliance A021602 Study - Cabozantinib vs. Placebo for Advanced Neuroendocrine Tumours After Progression on Prior Therapy"

By ecancer FEATURING Jennifer Chan
By ecancer FEATURING Jennifer Chan
0 views
November 14, 2023
Comments 0
Login to view comments. Click here to Login